pharmaphorum4d
Novartis gets FDA OK for first in its trio of IgAN therapies
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
pharmaphorum2d
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Business Insider1mon
Vera reaction to competitor IgAN update ‘overdone,’ says Goldman Sachs
The firm, which notes that Vera is conducting the Phase 3 ORIGIN 3 study of 150 mg atacicept in patients with IgAN while utilizing at-home administration with once-weekly dosing, reiterates a Buy ...
Nature2mon
The Oxford classification—predicting progression of IgAN
The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...
Seeking Alpha1mon
Vera plunges as Otsuka updates on rival therapy
Despite potential volatility ahead of the readouts, “We continue to recommend the stock as the profile is greatly derisked & will benefit from first-ish mover advantage in IgAN, a field ...
Nature3y
Breaking new ground with a late-phase rare-disease pipeline
Having been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN), Calliditas is awaiting regulatory approval decisions in the US and European ...